Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.

Our study aims to investigate the effect of a low-dose pioglitazone regimen on bone mineral density and bone formation-resorption markers in control and diabetic rats. Wistar rats were divided into 4 groups: non-diabetic controls, control rats receiving pioglitazone (3 mg/kg), streptozocin-treated diabetic rats (50 mg/kg), diabetic rats treated with pioglitazone (3 mg/kg). The duration of the experiment was 8 weeks. Diabetes in our rats was associated with weight loss, increased urinary calcium excretion and reduced plasma osteocalcin levels. Diabetes mellitus did not affect bone mineral density. Pioglitazone administration had no impact on bone formation and resorption markers levels and did not modify bone mineral density in the four studied groups. Pioglitazone at the 3 mg/kg dose was not associated with significant skeletal complications in our experimental model.

Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs.

The treatment of Alzheimer's disease is undoubtedly one of the greatest challenges of modern medicine and pharmacology. Affecting millions of people, Alzheimer's disease has become a major social problem. Several theories have been proposed to account for its pathogenesis. Possibly, the "amyloid cascade hypothesis" is the dominant one. However, the "inflammation hypothesis" also contributes to the pathogenesis of the disease. Thus, this study intends to describe the role of neuroinflammation in Alzheimer's disease, regarding its cellular and molecular components, and to examine if the use of non-steroidal anti-inflammatory drugs could be an effective "weapon" in the battle against it.